Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06415942 · ClinicalTrials.gov registry record · NA

Assessing the Maternal Outcome Monitoring Systems

A NA study of Maternal Death and Maternal Complication of Pregnancy, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
2
Study locations

NCT06415942: Recruiting NA study of Maternal Death and Maternal Complication of Pregnancy, sponsored by Columbia University.

NCT06415942 is a NA study of Maternal Death and Maternal Complication of Pregnancy that is actively recruiting participants, run by Columbia University. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06415942, a NA study of Maternal Death and Maternal Complication of Pregnancy, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

Pregnancy-related death is a growing public health issues, which are of particular concern to minority groups, including African-Americans and Spanish-speaking Latinas. Our proposal aims to improve a patient's ability to detect warning signs of pregnancy related death and seek medical care.

Primary Outcome

Change in patient activation measured using the validated Patient Activation Measure (PAM)

Interventions

  • OTHER Maternal Outcome Monitoring and Support system

Study Locations (2)

New York

  • NewYork-Presbyterian Columbia University Irving Medical Center - New York
  • NewYork-Prebyterian/Weill Cornell Medical Center - New York

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-12-11
Est. Completion 2027-01-31
Phase NA
Columbia University

958 total trials

What NCT06415942 shows while recruiting

NCT06415942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Maternal Death appearing as the primary indexed condition, and to 1 intervention - of which Maternal Outcome Monitoring and Support system is the first listed.

NCT06415942 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06415942 about?

NCT06415942 is a clinical study titled "Assessing the Maternal Outcome Monitoring Systems". Pregnancy-related death is a growing public health issues, which are of particular concern to minority groups, including African-Americans and Spanish-speaking Latinas. Our proposal aims to improve a patient's ability to detect warning signs of pregnancy related death and seek medical care.

What is the current status of trial NCT06415942?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-12-11. Estimated completion is 2027-01-31.

What conditions does trial NCT06415942 study?

This clinical trial studies the following conditions: Maternal Death, Maternal Complication of Pregnancy.

What interventions are being tested in trial NCT06415942?

The interventions under investigation include: Maternal Outcome Monitoring and Support system (OTHER).

Who is sponsoring clinical trial NCT06415942?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06415942 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Maternal Death

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06415942's enrollment target sits among peer trials

80 995th of 2000 higher than 941 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06415942, the US trial registry maintained by the National Library of Medicine. NCT06415942 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.